Legislation states that cumulative risk assessment (CRA) is to be performed to assess the risk to the population of chemicals expected to occur together, when methodology is available. To support the implementation of CRA in a regulatory context, available methodology is implemented in the Monte Carlo Risk Assessment (MCRA) platform developed by Wageningen University & Research (WUR, Biometris) for the Dutch Institute for Public Health and the Environment (RIVM), as part of the current EFSA‐RIVM Framework Partnership Agreement (FPA) (2021‐2025). The FPA focusses on the enhancement of the MCRA software for user‐friendly and transparent mixture risk assessment by developing new standard regulatory actions (SRAs) and refinement of existing SRAs. The current report describes the updates in the platform and SRAs, related to readily available retrospective and novel prospective CRA methodology. Retrospective CRA aims to estimate the possible risk for populations in a recent past period, whereas prospective CRA evaluates the possible risk in view of the approval of substances, authorisation of products or setting of maximum residue levels (MRLs). Additionally, the updates in underlying data, including occurrence data, and functionalities are described and outcomes of the SRAs are validated. Described future actions align with the needs for the day‐to‐day use of the SRAs by governmental regulators and will facilitate efficient risk assessment.
